Bo Chi

First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer

R. Pazdur, B. Rellahan, P. Cortazar, 2013, Clinical Cancer Research.